KRAS and lung carcinoma: Also, the fact that the College of American Pathologists (CAP), the International Association for the Study of Lung Cancer (IASLC), the Association for Molecular Pathology (AMP), and the European Society of Clinical Oncology (ESMO) do not recommend KRAS mutation testing in SCC (52, 53) may introduce bias in retrospective studies.